首页|Lindqvist-type Polyoxometalates Act as Anti-breast Cancer Drugs via Mitophagy-induced Apoptosis

Lindqvist-type Polyoxometalates Act as Anti-breast Cancer Drugs via Mitophagy-induced Apoptosis

扫码查看
Objective:Lindqvist-type polyoxometalates(POMs)exhibit potential antitumor activities.This study aimed to examine the effects of Lindqvist-type POMs against breast cancer and the underlying mechanism.Methods:Using different cancer cell lines,the present study evaluated the antitumor activities of POM analogues that were modified at the body skeleton based on molybdenum-vanadium-centered negative oxygen ion polycondensations with different side strains.Cell colony formation assay,autophagy detection,mitochondrial observation,qRT-PCR,Western blotting,and animal model were used to evaluate the antitumor activities of POMs against breast cancer cells and the related mechanism.Results:MO-4,a Lindqvist-type POM linking a proline at its side strain,was selected for subsequent experiments due to its low half maximal inhibitory concentration in the inhibition of proliferation of breast cancer cells.It was found that MO-4 induced the apoptosis of multiple types of breast cancer cells.Mechanistically,MO-4 activated intracellular mitophagy by elevating mitochondrial reactive oxygen species(ROS)levels and resulting in apoptosis.In vivo,breast tumor growth and distant metastasis were significantly reduced following MO-4 treatment.Conclusion:Collectively,the results of the present study demonstrated that the novel Lindqvist-type POM MO-4 may exhibit potential in the treatment of breast cancer.

antitumorbreast cancerpolyoxometalatemitochondriamitophagy

Chen-guang YAO、Zi-jia ZHAO、Ting TAN、Jiang-ning YAN、Zhong-wei CHEN、Jun-tao XIONG、Han-luo LI、Yan-hong WEI、Kang-hong HU

展开 >

Sino-German Biomedical Center,Hubei Provincial Key Laboratory of Industrial Microbiology,Cooperative Innovation Center of Industrial Fermentation(Ministry of Education & Hubei Province),Key Laboratory of Fermentation Engineering(Ministry of Education),National"111"Center for Cellular Regulation and Molecular Pharmaceutics,Hubei University of Technology,Wuhan 430068,China

Centerfor Evaluation of Hubei Medical Products Administration,Wuhan 430068,China

Open Project Funding of the Key Laboratory of Fermentation Engineering(Ministry of Education)Natural Science Foundation of Hubei ProvinceKey R&D Project of Hubei Provinceinitial funding of Hubei University of Technology

202209EF092021CFB2892022BCA018XJ2022002201

2024

当代医学科学(英文)
华中科技大学同济医学院

当代医学科学(英文)

影响因子:0.748
ISSN:2096-5230
年,卷(期):2024.44(4)
  • 1